Literature DB >> 6322983

Antagonistic actions of retinoic acid and dexamethasone on anchorage-independent growth and epidermal growth factor binding of normal rat kidney cells.

A B Roberts, M A Anzano, L C Lamb, J M Smith, M B Sporn.   

Abstract

Type beta transforming growth factor (TGF-beta), in combination with epidermal growth factor (EGF) can induce nonneoplastic normal rat kidney cells to express a transformed phenotype and to form colonies in soft agar. Retinoic acid by itself has no effect on colony formation; but at concentrations of 10(-9) M or greater, it can greatly enhance the response of the cells to EGF and TGF-beta, as measured by colony growth in soft agar and expression of a transformed morphology in monolayer culture. Dexamethasone, at concentrations above 10(-9) M, has an opposite effect, inhibiting the TGF-beta-dependent formation of colonies in soft agar and restoring a more normal morphology to the cells. Added simultaneously, these two modulators act antagonistically; at equimolar concentrations, their opposite effects on colony formation are canceled. Retinoic acid and dexamethasone also have opposite and antagonistic effects on the binding of 125I-labeled EGF to normal rat kidney cells. Retinoic acid enhances the binding of EGF up to 6-fold, while dexamethasone reduces the binding to 50 to 60% of control levels. These effects on EGF binding show a dose dependence similar to the effects on colony formation in soft agar and on morphology in monolayer culture. Optimal effects on binding are observed 40 to 60 hr after treatment of the cells. It can be concluded that the abilities of retinoic acid and dexamethasone to alter expression of the transformed phenotype induced by treatment of normal rat kidney cells with TGF-beta and EGF are mediated at least in part through their effects on the EGF receptor.

Entities:  

Mesh:

Substances:

Year:  1984        PMID: 6322983

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  7 in total

1.  Epidermal growth factor receptor-induced activator protein 1 activity controls density-dependent growth inhibition in normal rat kidney fibroblasts.

Authors:  Jorrit J Hornberg; Henk Dekker; Peter H J Peters; Petra Langerak; Hans V Westerhoff; Jan Lankelma; Everardus J J van Zoelen
Journal:  Mol Biotechnol       Date:  2006-10       Impact factor: 2.695

2.  Similar effects of adenovirus E1A and glucocorticoid hormones on the expression of the metalloprotease stromelysin.

Authors:  R Offringa; A M Smits; A Houweling; J L Bos; A J van der Eb
Journal:  Nucleic Acids Res       Date:  1988-12-09       Impact factor: 16.971

3.  Differential response to retinoic acid of Syrian hamster embryo fibroblasts expressing v-src or v-Ha-ras oncogenes.

Authors:  A M Jetten; J C Barrett; T M Gilmer
Journal:  Mol Cell Biol       Date:  1986-10       Impact factor: 4.272

4.  Retinoids stimulate periosteal bone resorption by enhancing the protein RANKL, a response inhibited by monomeric glucocorticoid receptor.

Authors:  H Herschel Conaway; Amir Pirhayati; Emma Persson; Ulrika Pettersson; Olle Svensson; Catharina Lindholm; Petra Henning; Jan Tuckermann; Ulf H Lerner
Journal:  J Biol Chem       Date:  2011-06-29       Impact factor: 5.157

5.  Bradykinin-induced growth inhibition of normal rat kidney (NRK) cells is paralleled by a decrease in epidermal-growth-factor receptor expression.

Authors:  E J Van Zoelen; P H Peters; G B Afink; S Van Genesen; D G De Roos; W Van Rotterdam; A P Theuvenet
Journal:  Biochem J       Date:  1994-03-01       Impact factor: 3.857

6.  Role of transforming growth factor-beta in the development of the mouse embryo.

Authors:  U Heine; E F Munoz; K C Flanders; L R Ellingsworth; H Y Lam; N L Thompson; A B Roberts; M B Sporn
Journal:  J Cell Biol       Date:  1987-12       Impact factor: 10.539

7.  Distribution and modulation of the cellular receptor for transforming growth factor-beta.

Authors:  L M Wakefield; D M Smith; T Masui; C C Harris; M B Sporn
Journal:  J Cell Biol       Date:  1987-08       Impact factor: 10.539

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.